Plain-English translation of NCT07006077 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is an early-stage trial testing a new treatment called hV01 for people with advanced pancreatic cancer. hV01 is a specially designed virus that is injected directly into the tumor to help the immune system fight the cancer. The trial will evaluate whether this treatment is safe and effective for patients whose cancer has stopped responding to standard therapies.
Advanced pancreatic cancer is very difficult to treat, and many patients do not respond well to existing chemotherapy or targeted drugs. This medication takes a different approach by using an engineered virus to stimulate the body's immune system to attack cancer cells directly.
You likely qualify if…
You likely don't qualify if…
You will visit the trial site to receive injections of the medication directly into your tumor on day 1 and day 15 of each 28-day treatment cycle. The injections may be guided using ultrasound to ensure accuracy. After each injection, you will be monitored for safety, and your tumor will be evaluated for response to treatment every 28 days. The trial involves a small number of patients (12 total) and will help doctors understand whether this new treatment approach is safe and whether it helps control pancreatic cancer.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China